Timothy James Larkin, MD | |
75 Herrick St. Suite 206, Lahey Cardiology, Beverly, Beverly, MA 01915-5900 | |
(978) 927-8400 | |
(978) 922-1452 |
Full Name | Timothy James Larkin |
---|---|
Gender | Male |
Speciality | Interventional Cardiology |
Experience | 42 Years |
Location | 75 Herrick St. Suite 206, Beverly, Massachusetts |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1215975578 | NPI | - | NPPES |
036078369 | Medicaid | IL | |
060063131 | Other | RAILROAD MEDICARE |
Facility Name | Location | Facility Type |
---|---|---|
Northeast Hospital Corporation | Beverly, MA | Hospital |
Lahey Hospital & Medical Center, Burlington | Burlington, MA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Lahey Clinic Inc | 2264336528 | 1211 |
News Archive
Amarin Corporation plc today announced it has closed its $70 million private placement. The transaction was led by existing investor, Fountain Healthcare Partners, on behalf of funds affiliated with other existing investors Sofinnova Ventures, Orbimed Advisors and Longitude Capital. The new investor group was led by funds affiliated with Abingworth LLP and included APG Asset Management, Great Point Partners, Tavistock Life Sciences Company and RA Capital. Cowen and Company, LLC acted as the exclusive placement agent for the transaction.
Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).
In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group.
Today the National Autism Association announced its support of H.R. 4247, the Preventing Harmful Restraint and Seclusion in Schools Act, introduced Wednesday by Congressman George Miller (D-CA) and Congresswoman Cathy McMorris Rodgers (R-WA). The federal bill is a much-anticipated solution to the issues of unregulated restraint and seclusion in schools.
Today at the inaugural Beyond Sequencing conference in San Francisco, EdgeBio introduced their Science as a Service concept built on top of CLC bio's enterprise platform, CLC Genomics Server. EdgeBio's end-to-end service concept leads each scientist and project from conception and project design through bioinformatics and analysis.
› Verified 9 days ago
Entity Name | Lahey Clinic Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1538194980 PECOS PAC ID: 2264336528 Enrollment ID: O20031120000097 |
News Archive
Amarin Corporation plc today announced it has closed its $70 million private placement. The transaction was led by existing investor, Fountain Healthcare Partners, on behalf of funds affiliated with other existing investors Sofinnova Ventures, Orbimed Advisors and Longitude Capital. The new investor group was led by funds affiliated with Abingworth LLP and included APG Asset Management, Great Point Partners, Tavistock Life Sciences Company and RA Capital. Cowen and Company, LLC acted as the exclusive placement agent for the transaction.
Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).
In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group.
Today the National Autism Association announced its support of H.R. 4247, the Preventing Harmful Restraint and Seclusion in Schools Act, introduced Wednesday by Congressman George Miller (D-CA) and Congresswoman Cathy McMorris Rodgers (R-WA). The federal bill is a much-anticipated solution to the issues of unregulated restraint and seclusion in schools.
Today at the inaugural Beyond Sequencing conference in San Francisco, EdgeBio introduced their Science as a Service concept built on top of CLC bio's enterprise platform, CLC Genomics Server. EdgeBio's end-to-end service concept leads each scientist and project from conception and project design through bioinformatics and analysis.
› Verified 9 days ago
Entity Name | Lahey Clinic Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1063447316 PECOS PAC ID: 2264336528 Enrollment ID: O20040629001269 |
News Archive
Amarin Corporation plc today announced it has closed its $70 million private placement. The transaction was led by existing investor, Fountain Healthcare Partners, on behalf of funds affiliated with other existing investors Sofinnova Ventures, Orbimed Advisors and Longitude Capital. The new investor group was led by funds affiliated with Abingworth LLP and included APG Asset Management, Great Point Partners, Tavistock Life Sciences Company and RA Capital. Cowen and Company, LLC acted as the exclusive placement agent for the transaction.
Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).
In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group.
Today the National Autism Association announced its support of H.R. 4247, the Preventing Harmful Restraint and Seclusion in Schools Act, introduced Wednesday by Congressman George Miller (D-CA) and Congresswoman Cathy McMorris Rodgers (R-WA). The federal bill is a much-anticipated solution to the issues of unregulated restraint and seclusion in schools.
Today at the inaugural Beyond Sequencing conference in San Francisco, EdgeBio introduced their Science as a Service concept built on top of CLC bio's enterprise platform, CLC Genomics Server. EdgeBio's end-to-end service concept leads each scientist and project from conception and project design through bioinformatics and analysis.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Timothy James Larkin, MD 75 Herrick St Ste 206, Beverly, MA 01915-5900 Ph: (978) 927-8400 | Timothy James Larkin, MD 75 Herrick St. Suite 206, Lahey Cardiology, Beverly, Beverly, MA 01915-5900 Ph: (978) 927-8400 |
News Archive
Amarin Corporation plc today announced it has closed its $70 million private placement. The transaction was led by existing investor, Fountain Healthcare Partners, on behalf of funds affiliated with other existing investors Sofinnova Ventures, Orbimed Advisors and Longitude Capital. The new investor group was led by funds affiliated with Abingworth LLP and included APG Asset Management, Great Point Partners, Tavistock Life Sciences Company and RA Capital. Cowen and Company, LLC acted as the exclusive placement agent for the transaction.
Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).
In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group.
Today the National Autism Association announced its support of H.R. 4247, the Preventing Harmful Restraint and Seclusion in Schools Act, introduced Wednesday by Congressman George Miller (D-CA) and Congresswoman Cathy McMorris Rodgers (R-WA). The federal bill is a much-anticipated solution to the issues of unregulated restraint and seclusion in schools.
Today at the inaugural Beyond Sequencing conference in San Francisco, EdgeBio introduced their Science as a Service concept built on top of CLC bio's enterprise platform, CLC Genomics Server. EdgeBio's end-to-end service concept leads each scientist and project from conception and project design through bioinformatics and analysis.
› Verified 9 days ago
Ronald Newman, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 85 Herrick St, Lahey At Beverly Hospital, Beverly, MA 01915 Phone: 978-922-3000 | |
Joel W Shelkrot, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: Beverly Hospital, Herrick Street, Beverly, MA 01915 Phone: 978-922-3000 | |
Dr. Ariadne Stephanie Scott Iriarte, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 85 Herrick St, Beverly, MA 01915 Phone: 978-922-3000 | |
Pierre Abou-ezzi, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Cummings Center, Suite 126q, Beverly, MA 01915 Phone: 978-524-8181 Fax: 978-524-9868 | |
Thuy Le, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 85 Herrick St, Beverly, MA 01915 Phone: 978-922-3000 Fax: 978-524-6088 | |
Dr. David Goldberg, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: Lahey Cardiology, Beverly, 75 Herrick Street Suite 206, Beverly, MA 01915 Phone: 978-927-8400 Fax: 978-922-1452 | |
Dorina Omari, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 100 Cummings Ctr, Suite 166 D, Beverly, MA 01915 Phone: 978-712-3360 Fax: 978-712-3392 |